Biosimilar deemed equivalent to rituximab in FL

Print Friendly, PDF & Email


Micrograph showing
follicular lymphoma
Phase 3 results suggest the biosimilar product CT-P10 is equivalent to rituximab in patients with low-tumor-burden follicular lymphoma (FL). Overall response rates were similar—both exceeding 80%—in patients who received CT-P10 and those who received rituximab. In addition, adverse event (AE) profiles were comparable between the treatment arms.... [Read Article]
Print Friendly, PDF & Email

Combo appears safe, active in rel/ref NHL

Print Friendly, PDF & Email


Micrograph showing
follicular lymphoma
The combination of Hu5F9-G4 (5F9) and rituximab was considered safe and produced durable complete responses (CRs) in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) in a phase 1b trial. Mainly low-grade adverse events (AEs) were observed with rituximab and 5F9, a macrophage-activating immune checkpoint inhibitor blocking CD47. In addition,... [Read Article]
Print Friendly, PDF & Email

Sandoz won’t seek U.S. approval for rituximab biosimilar

Print Friendly, PDF & Email


Vials and a syringe
Sandoz has decided not to pursue U.S. approval for its rituximab product (GP2013), a proposed biosimiliar of Rituxan/Mabthera. GP2013 (Rixathon, Riximyo) is already approved outside the U.S. Sandoz was seeking U.S. approval of GP2013 for all the same indications as the reference product—B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis,... [Read Article]
Print Friendly, PDF & Email

FDA approves duvelisib for CLL/SLL and FL

Print Friendly, PDF & Email


Micrograph showing CLL
The U.S. Food and Drug Administration (FDA) has approved duvelisib (Copiktra™), a dual PI3K delta/gamma inhibitor, for two indications. Duvelisib has full FDA approval to treat adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have received at least two prior therapies. Duvelisib also has accelerated approval to... [Read Article]
Print Friendly, PDF & Email

Risks of watchful waiting in follicular lymphoma

Print Friendly, PDF & Email


Micrograph showing
follicular lymphoma
A subset of follicular lymphoma (FL) patients managed with watchful waiting are vulnerable to organ dysfunction and transformation, according to research published in Clinical Lymphoma, Myeloma & Leukemia. In a retrospective study, about 24% of FL patients managed with watchful waiting developed significant organ dysfunction or transformation at first progression over... [Read Article]
Print Friendly, PDF & Email

Regimens produce similar results in FL

Print Friendly, PDF & Email


Micrograph showing
follicular lymphoma
Rituximab plus lenalidomide had efficacy similar to that of rituximab plus chemotherapy in the treatment of follicular lymphoma (FL) in a phase 3 trial. Patients with previously untreated FL had similar complete response (CR) rates and progression-free survival (PFS) rates whether they received rituximab-based chemotherapy or rituximab plus lenalidomide. These results... [Read Article]
Print Friendly, PDF & Email

Treatment improves PFS in early stage FL

Print Friendly, PDF & Email


Micrograph showing FL
A multidrug regimen can improve upon involved-field radiotherapy (IFRT) in patients with early stage follicular lymphoma (FL), according to research published in the Journal of Clinical Oncology. FL patients who received IFRT plus cyclophosphamide, vincristine, and prednisolone (CVP)—with or without rituximab—had a significant improvement in progression-free survival (PFS) compared to patients who... [Read Article]
Print Friendly, PDF & Email

Health Canada expands approval of obinutuzumab

Print Friendly, PDF & Email


Obinutuzumab (Gazyva)
Health Canada has expanded the approved use of obinutuzumab (Gazyva®). The anti-CD20 monoclonal antibody is now approved for use in combination with chemotherapy to treat patients with previously untreated follicular lymphoma (FL) that is advanced (stage II bulky, stage III, or stage IV). In patients who respond to this treatment, obinutuzumab monotherapy can... [Read Article]
Print Friendly, PDF & Email

Transplant strategy not viable for aggressive B-NHL

Print Friendly, PDF & Email


HSCT preparation
Photo by Chad McNeeley
Transplant with radioimmunotherapy (RIT)-based conditioning is a viable treatment option for patients with indolent—but not aggressive—B-cell non-Hodgkin lymphomas (NHLs), according to researchers. Long-term follow-up data showed “excellent” outcomes in patients with indolent B-NHL who received conditioning with 90Y-ibritumomab tiuxetan plus fludarabine and low-dose total body irradiation (TBI) prior... [Read Article]
Print Friendly, PDF & Email